Haleon (HLN) Reports 3% Organic Growth in 2025 Driven by ‘Win as One’ Strategy

Haleon (NYSE:HLN) is one of the most promising stocks under $20. On February 25, Haleon reported financial performance for the full-year 2025, marked by the introduction of its ‘Win as One’ strategy and an organic revenue growth of 3%. While results in North America were tempered by low consumer confidence and a weak cold and flu season, the company saw strong expansion in its EMEA, Latin America, and Asia-Pacific regions.

Total revenue reached £11.03 billion, supported by the Oral Health sector, which outperformed with ~8% organic growth. These results allowed the company to maintain or gain market share in 60% of its business segments. Profitability was driven by aggressive productivity initiatives, including a 26% reduction in SKU complexity and optimized logistics. Despite market challenges, the company continued to reinvest in its future, increasing spending on R&D by 7.7%.

For 2026, Haleon (NYSE:HLN) expects organic revenue growth to accelerate to between 3% and 5%, supported by a new operating model designed to increase agility. The company has created a Chief Growth Officer role and restructured into six specific operating units to better capture regional opportunities. Management plans to deliver high single-digit adjusted operating profit growth and has allocated £500 million for share buybacks in the coming year.

Haleon (NYSE:HLN), together with its subsidiaries, researches, develops, manufactures, and sells various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 33 Stocks That Should Double in 3 Years.

Disclosure: None. Follow Insider Monkey on Google News.